STALICLA

Executive Summary

STALICLA is a Swiss clinical-stage biotech company pioneering precision medicine for neurodevelopmental disorders (NDDs), including Autism Spectrum Disorder (ASD). The company leverages its proprietary DEPI platform to identify patient subgroups and develop targeted small molecule therapies. Its lead program, STP-01, targets a specific neurophysiological subtype of ASD, with Phase 1/2 clinical data expected in the near term. The company's approach aims to address the high heterogeneity in NDDs by stratifying patients based on underlying biology, potentially improving treatment outcomes. As a private company founded in 2017 and headquartered in Geneva, STALICLA is positioned at the forefront of precision psychiatry, though it faces typical early-stage risks including clinical trial uncertainty and the need for additional financing. The DEPI platform offers a competitive advantage by enabling patient stratification, which could accelerate development and increase probability of success in later-stage trials. Key upcoming milestones include clinical data readouts and potential partnerships.

Upcoming Catalysts (preview)

• Q3 2026Phase 1/2 clinical data for STP-01 in ASD subtype40% success
• Q4 2026Announcement of strategic partnership or licensing deal50% success
• H2 2026Series B or follow-on financing round60% success